Pharma News

(3rd September, 2014); The new agent, an angiotensin receptor-neprilysin inhibitor (ARNI) known as LCZ696, has already been granted Fast Track status by the United States Food and Drug Administration (FDA) – a designation which can expedite the review of new medicines intended to treat serious or life-threatening conditions. And surprisingly, LCZ696 was superior to ACE-inhibitor, enalapril, on key endpoints in the largest heart failure study ever done.

Initial human testing of an investigational vaccine to prevent Ebola virus disease will begin soon by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.

(2nd September, 2014); Wockhardt Ltd’s New Drug Discovery program in Anti - Infective research received a major boost after two of its drugs, WCK 771 and WCK 2349, received the coveted Qualified Infectious Disease Product (QIDP) status from the US FDA. This is the first instance of an Indian Pharmaceutical company receiving a QIDP status.

[adsense:336x280:8701650588]

(2nd September, 2014; Business Wire India); Five years on from the first breakthrough presentation of the pivotal RE-LY^® clinical trial of Pradaxa^® (dabigatran etexilate) for the prevention of stroke in non-valvular atrial fibrillation (NVAF), extensive clinical trial and real-world data support Pradaxa^® in various indications. Boehringer Ingelheim continues to grow the evidence base for Pradaxa^® to improve care for patients at risk of blood clots and today announces the initiation of Phase III of the GLORIA™-AF registry program in North America and in Europe. During this final phase of the registry program, data on the overall safety and effectiveness of antithrombotic treatments will be collected.

(22nd August, 2014; Business Wire India); Celgene Corporation (NASDAQ:CELG) announced that results of a study evaluating the combination of REVLIMID® (lenalidomide) with rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine sulfate and prednisone (R-CHOP) in untreated diffuse large b-cell lymphoma (DLBCL) were published online ahead of print in the Journal of Clinical Oncology.

(22nd August, 2014); Due to effective vaccination, polio is comletely eradiated from India and World Health Organisation (WHO) presented official certification to India for its ‘Polio Free’ status in March 2014. But it seems like polio itself doesn't want to give up and wants to extend its victims. Researchers alaraming findings notified mutated poliovirus that can resist vaccine protection to a considerable extent was found in victims of an outbreak in the Congo in 2010. The pathogen could also potentially have infected many people in Germany. The results appear now in the magazine PNAS.

(13th August, 2014); Dr Harsh Vardhan, Minister for Health, has clarified that India does not have any confirmed or even suspected Ebola virus affected person. World Health Organization (WHO) had informed that one Indian passenger had travelled on the same flight in which Ebola virus patient (foreign national) was travelling from Monrovia to Lagos. This Indian passenger is back in India. He has been tracked and his health is being regularly monitored. The Health Minister said “We are happy to share that the said person is healthy, fit and fine.”

(7th August, 2014); First time, Scientists are able to cure Rheumatoid arthritis in animals with help of new drug. The researchers are now planning  for human studies to identify the efficacy of the medicinal product in humans.

(7th August, 2014); Electromagnetic stimulation can alter brain organization and it may reprogram your brain for better performance shown by investigators from The University of Western Australia.

(6th August, 2014); Sanofi in India announced today that it has entered into a marketing and distribution agreement with Emcure Pharmaceuticals (Emcure) for its oncology portfolio in India. As per the agreement, while Sanofi will continue to own its oncology range - comprising 4 brands namely Taxotere®, Jevtana®, Fludara® and Fasturtec®, Emcure will market and distribute these brands through its Specialty Unit.